Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Depreciation & Amortization (CF) (2016 - 2024)

Historic Depreciation & Amortization (CF) for Spero Therapeutics (SPRO) over the last 9 years, with Q2 2024 value amounting to $2000.0.

  • Spero Therapeutics' Depreciation & Amortization (CF) fell 9814.81% to $2000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $2000.0, marking a year-over-year decrease of 9921.26%. This contributed to the annual value of $2000.0 for FY2024, which is 9945.5% down from last year.
  • Per Spero Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2000.0 for Q2 2024, which was down 9814.81% from $38000.0 recorded in Q4 2023.
  • Spero Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $294000.0 for Q2 2022, and its period low was $2000.0 during Q2 2024.
  • For the 5-year period, Spero Therapeutics' Depreciation & Amortization (CF) averaged around $157882.4, with its median value being $159000.0 (2021).
  • As far as peak fluctuations go, Spero Therapeutics' Depreciation & Amortization (CF) soared by 47704.92% in 2020, and later crashed by 9814.81% in 2024.
  • Spero Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $230000.0 in 2020, then decreased by 16.96% to $191000.0 in 2021, then plummeted by 32.46% to $129000.0 in 2022, then plummeted by 70.54% to $38000.0 in 2023, then tumbled by 94.74% to $2000.0 in 2024.
  • Its last three reported values are $2000.0 in Q2 2024, $38000.0 for Q4 2023, and $108000.0 during Q3 2023.